Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: A phase I study in patients with advanced solid malignancies
Antineoplastic Combined Chemotherapy Protocols
Receptor, Epidermal Growth Factor
Dual EGFR inhibition with cetuximab and erlotinib is feasible; the observed toxicities were manageable and consistent with the safety profiles of the individual drugs. The recommended doses for phase II studies are 250 mg/m(2) i.v. weekly for cetuximab and 150 mg daily orally for erlotinib.